Investor Relations

Overview

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a commercial-stage biopharmaceutical company focused on AI-based drug re-innovation in neuroscience and immuno-oncology.  We expedite the discovery and development of new indications for existing late-stage drug candidates and/or approved drugs by leveraging a composite of AI tools and approaches.  

Discovered and developed through this AI-driven method, our commercial product, IGALMI™ (dexmedetomidine) sublingual film (BXCL501), is approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The safety and effectiveness of IGALMI have not been established beyond 24 hours from the first dose. For more information, please visit igalmi.com and also see the IGALMI full Prescribing Information.
 
BXCL501 is under evaluation for the acute treatment of agitation associated with Alzheimer’s dementia in care settings and for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. The safety and efficacy of BXCL501 for these uses have not been established.